Twenty-year medication use trends in first-episode bipolar disorder.

Authors:
Poranen J; Koistinaho A; Tanskanen A; Tiihonen J; Taipale H and 1 more

Journal:
Acta Psychiatr Scand

Publication Year: 2022

DOI:
10.1111/acps.13504

PMCID:
PMC9828455

PMID:
36177718

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Acta Psychiatr Scand

Abbreviation: Acta Psychiatr Scand

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Psychiatry

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder.
Strawbridge R; Kurana S; Kerr-Gaffney J and 4 more (2022) - Transparency Score: 3/6
Autism and self-harm: A population-based and discordant sibling study of young individuals.
Stark I; Rai D; Lundberg M and 4 more (2022) - Transparency Score: 2/6
Characteristics and predictors of off-label use of antipsychotics in general population sample.
Pirhonen E; Haapea M; Rautio N and 7 more (2022) - Transparency Score: 3/6
Childhood symptoms of attention-deficit/hyperactivity disorder and borderline personality disorder.
Tiger A; Ohlis A; Bjureberg J and 6 more (2022) - Transparency Score: 3/6
Childhood temperamental, emotional, and behavioral characteristics associated with mood and anxiety…
Bakken NR; Hannigan LJ; Shadrin A and 6 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST Jari Tiihonen, Heidi Taipale and Antti Tanskanen have participated in research projects funded by grants from Janssen‐Cilag and Eli Lilly to their employing institution. Heidi Taipale reports personal fees from Janssen‐Cilag and Otsuka. Jari Tiihonen reports personal fees from Eli Lilly, Evidera, Janssen‐Cilag, Lundbeck, Mediuutiset, Otsuka, Sidera, and Suvovion; and is a consultant to Orion and HLS Therapeutics. Markku Lähteenvuo is a board member of Genomi Solutions Ltd., Nursie Health Ltd., and Springflux Ltd. has received honoraria from Sunovion, Orion Pharma, Lundbeck, Otsuka Pharma, Recordati, Janssen and Janssen‐Cilag and research funding from the Finnish Cultural Foundation and the Emil Aaltonen Foundation."

Evidence found in paper:

"FUNDING INFORMATION None."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025